Medtronic (NYSE:MDT) announces the FDA nod for its InterStim Micro sacral nerve modulator (SNM) for the treatment of overactive bladder, fecal incontinence and non-obstructive urinary retention. The company says the device is the world’s smallest, half the size of other SNM products.
The FDA also approved the InterStim SureScan MRI leads that are used with the InterStim Micro and recharge-free InterStim II devices and allow full-body 1.5T and 3T MRI-conditional scans.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.